CA2938466C - Methods of treating alzheimer's disease - Google Patents

Methods of treating alzheimer's disease Download PDF

Info

Publication number
CA2938466C
CA2938466C CA2938466A CA2938466A CA2938466C CA 2938466 C CA2938466 C CA 2938466C CA 2938466 A CA2938466 A CA 2938466A CA 2938466 A CA2938466 A CA 2938466A CA 2938466 C CA2938466 C CA 2938466C
Authority
CA
Canada
Prior art keywords
agent
patient
group
crenezumab
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2938466A
Other languages
English (en)
French (fr)
Other versions
CA2938466A1 (en
Inventor
William Cho
Michel Friesenhahn
Robert Paul
Michael Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52684643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2938466(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2938466A1 publication Critical patent/CA2938466A1/en
Application granted granted Critical
Publication of CA2938466C publication Critical patent/CA2938466C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2938466A 2014-02-08 2015-02-06 Methods of treating alzheimer's disease Active CA2938466C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461937472P 2014-02-08 2014-02-08
US61/937,472 2014-02-08
US201461971479P 2014-03-27 2014-03-27
US61/971,479 2014-03-27
US201462010259P 2014-06-10 2014-06-10
US62/010,259 2014-06-10
US201462081992P 2014-11-19 2014-11-19
US62/081,992 2014-11-19
PCT/US2015/014758 WO2015120233A1 (en) 2014-02-08 2015-02-06 Methods of treating alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2938466A1 CA2938466A1 (en) 2015-08-13
CA2938466C true CA2938466C (en) 2021-11-02

Family

ID=52684643

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938466A Active CA2938466C (en) 2014-02-08 2015-02-06 Methods of treating alzheimer's disease

Country Status (19)

Country Link
US (3) US20150246963A1 (enExample)
EP (2) EP3102231B1 (enExample)
JP (4) JP6685912B2 (enExample)
KR (4) KR20230056800A (enExample)
CN (1) CN106163548A (enExample)
AU (1) AU2015214058B2 (enExample)
BR (1) BR112016018170A2 (enExample)
CA (1) CA2938466C (enExample)
CL (2) CL2016001979A1 (enExample)
HK (1) HK1231401A1 (enExample)
IL (1) IL246999B (enExample)
MX (1) MX380252B (enExample)
MY (1) MY179105A (enExample)
NZ (1) NZ723884A (enExample)
RU (1) RU2724190C2 (enExample)
SG (2) SG11201606316XA (enExample)
TW (1) TWI705824B (enExample)
WO (1) WO2015120233A1 (enExample)
ZA (1) ZA201605341B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015230972B2 (en) * 2014-03-21 2021-05-27 Alzheon, Inc. Methods for treating neurological disorders
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
CN108289870A (zh) * 2015-09-10 2018-07-17 阿尔泽恩股份有限公司 治疗特定患者群体的神经变性病症的方法
CA3003435A1 (en) * 2015-10-28 2017-05-04 The Trustees Of The University Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
IL263433B2 (en) * 2016-06-07 2024-03-01 Biogen Int Neuroscience Gmbh Methods for treating alzheimer's disease
CN109952097A (zh) * 2016-07-29 2019-06-28 生物切萨皮克有限责任公司 治疗或预防与阿尔茨海默病治疗相关的淀粉样蛋白相关成像异常的方法
IT201600118499A1 (it) * 2016-11-25 2018-05-25 Giacomo Koch Uso di agonisti dopaminergici per la prevenzione della progressione della malattia di Alzheimer allo stadio precoce.
WO2018207154A1 (en) * 2017-05-12 2018-11-15 The Hong Kong University Of Science And Technology Heterocyclic compounds as epha4 inhibitors
DK3672631T5 (da) 2017-08-22 2024-08-26 Biogen Ma Inc Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DE602004026470D1 (de) 2003-11-05 2010-05-20 Roche Glycart Ag Fc-rezeptor und effektorfunktion
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2374817B1 (en) 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
KR101667623B1 (ko) * 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
MY167887A (en) * 2005-12-12 2018-09-26 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008011348A2 (en) * 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
EP2451348A4 (en) * 2010-04-13 2013-07-31 Baxter Int USE OF THE VENTRICULAR MAGNITUDE RATE IN INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF MORBUS ALZHEIMER
CN103179981B (zh) * 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
JP2014001232A (ja) * 2013-09-02 2014-01-09 Janssen Alzheimer Immunotherapy アミロイド原性疾患の処置

Also Published As

Publication number Publication date
TWI705824B (zh) 2020-10-01
IL246999A0 (en) 2016-09-29
NZ723884A (en) 2023-02-24
KR20160111039A (ko) 2016-09-23
SG11201606316XA (en) 2016-08-30
RU2016136081A (ru) 2018-03-13
CL2017002781A1 (es) 2018-04-13
ZA201605341B (en) 2021-01-27
JP2017511793A (ja) 2017-04-27
WO2015120233A1 (en) 2015-08-13
CN106163548A (zh) 2016-11-23
CA2938466A1 (en) 2015-08-13
EP3102231A1 (en) 2016-12-14
US20220195020A1 (en) 2022-06-23
BR112016018170A2 (pt) 2018-02-20
KR20210121288A (ko) 2021-10-07
EP3718563A1 (en) 2020-10-07
JP2024037893A (ja) 2024-03-19
US20200399352A1 (en) 2020-12-24
RU2016136081A3 (enExample) 2018-09-28
MX2016010173A (es) 2016-10-13
TW201613636A (en) 2016-04-16
AU2015214058A1 (en) 2016-08-11
JP2020073507A (ja) 2020-05-14
RU2724190C2 (ru) 2020-06-23
SG10201913637RA (en) 2020-03-30
JP2022058369A (ja) 2022-04-12
CL2016001979A1 (es) 2017-02-10
KR20240094017A (ko) 2024-06-24
MX380252B (es) 2025-03-12
KR20230056800A (ko) 2023-04-27
AU2015214058B2 (en) 2020-07-09
JP6685912B2 (ja) 2020-04-22
HK1231401A1 (zh) 2017-12-22
EP3102231B1 (en) 2019-09-11
US20150246963A1 (en) 2015-09-03
MY179105A (en) 2020-10-28
IL246999B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
CA2938466C (en) Methods of treating alzheimer's disease
JP2017511793A5 (enExample)
JP6727259B2 (ja) パーキンソン病の治療のための新規治療方法
CN113018300B (zh) 用于治疗神经病症的方法
Zheng et al. Icariin targets Nrf2 signaling to inhibit microglia-mediated neuroinflammation
US9248111B2 (en) Therapeutic approaches for treating parkinson's disease
CN104487429A (zh) 杂环黄酮衍生物、组合物及与其相关的方法
JP2011522035A (ja) パーキンソン病治療医薬組成物
JP2020534299A5 (enExample)
JP2024069257A (ja) Ｌ－４－クロロキヌレニンの剤形及び治療的使用
Mueller II et al. Sigma-1 receptor stimulation protects retinal ganglion cells from ischemia-like insult through the activation of extracellular-signal-regulated kinases 1/2
Dickinson et al. Rapamycin does not affect post-absorptive protein metabolism in human skeletal muscle
KR20130099815A (ko) 글루코코르티코이드에 기초한 조성물의 약량학 및 투여
D'Espessailles et al. Calcium sensing receptor activation in THP-1 macrophages triggers NLRP3 inflammasome and human preadipose cell inflammation
RU2642962C2 (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
MX2015001889A (es) Laquinimod para tratamiento de trastornos mediados por receptor de canabinoide tipo 1 (cb1).
TW201247612A (en) Compositions for treating kidney disorders
Turchan et al. Neuroprotective therapy for HIV dementia
BR112019015023A2 (pt) Intensificadores de canibalismo celular para uso para sensibilizar tumores para terapia por radiação
Chen et al. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling
JP2011506607A5 (enExample)
JP2019504101A (ja) 神経障害の新規の併用療法
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
KR20190082841A (ko) 피부 병태를 치료하기 위한 티아졸 및 코르티코스테로이드를 포함하는 조합 치료
JP2022538898A (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200204